| A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP) (NCT02417935) | Eli Lilly and Company | 2015-04-01 |
| A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis (NCT02387801) | Eli Lilly and Company | 2015-04-01 |
| A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS). (NCT02431754) | Eli Lilly and Company | 2015-04-01 |
| Lasmiditan Compared to Placebo in the Acute Treatment of Migraine: (NCT02439320) | Eli Lilly and Company | 2015-04-01 |
| A Study of Olaratumab in Japanese Participants With Advanced Cancer (NCT02377752) | Eli Lilly and Company | 2015-03-23 |
| A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment (NCT02387814) | Eli Lilly and Company | 2015-03-01 |
| A Study of LY2409021 Formulations in Healthy Participants (NCT02385084) | Eli Lilly and Company | 2015-03-01 |
| Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents (NCT02402933) | Eli Lilly and Company | 2015-03-01 |
| A Study of LY3154207 in Healthy Participants (NCT02365571) | Eli Lilly and Company | 2015-02-01 |
| A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children (NCT02370485) | Eli Lilly and Company | 2015-02-01 |
| A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer (NCT02359058) | Eli Lilly and Company | 2015-02-01 |
| A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus (NCT02106364) | Eli Lilly and Company | 2015-02-01 |
| A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma (NCT02326025) | Eli Lilly and Company | 2015-01-22 |
| A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (NCT02314117) | Eli Lilly and Company | 2015-01-20 |
| Food-Effect Study in Healthy Participants (NCT02233296) | Eli Lilly and Company | 2015-01-01 |
| A Study of LY3143753 and LY3185643 in Healthy Participants (NCT02342314) | Eli Lilly and Company | 2015-01-01 |
| A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants (NCT02365558) | Eli Lilly and Company | 2015-01-01 |
| A Study of LY900014 Formulations in Healthy Participants (NCT02317575) | Eli Lilly and Company | 2015-01-01 |
| A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants (NCT02340104) | Eli Lilly and Company | 2015-01-01 |
| A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes (NCT02806973) | Eli Lilly and Company | 2015-01-01 |
| A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women (NCT02337387) | Eli Lilly and Company | 2015-01-01 |
| An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480) (NCT02335346) | Eli Lilly and Company | 2015-01-01 |
| A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia (NCT02260648) | Eli Lilly and Company | 2015-01-01 |
| A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma (NCT02423343) | Eli Lilly and Company | 2015-01-01 |
| A Study of LY2835219 in Healthy Participants (NCT02327143) | Eli Lilly and Company | 2015-01-01 |
| A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (NCT02349295) | Eli Lilly and Company | 2014-12-31 |
| A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus (NCT02302716) | Eli Lilly and Company | 2014-12-01 |
| A Study of Lispro Formulations in Healthy Participants (NCT02293551) | Eli Lilly and Company | 2014-12-01 |
| A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease (NCT02323334) | Eli Lilly and Company | 2014-12-01 |
| A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) (NCT02240433) | Eli Lilly and Company | 2014-11-12 |
| A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (NCT02246621) | Eli Lilly and Company | 2014-11-06 |
| A Study of LY2623091 in Healthy Participants (NCT02300259) | Eli Lilly and Company | 2014-11-01 |
| A Study of Baricitinib in Healthy Japanese Participants (NCT02263911) | Eli Lilly and Company | 2014-11-01 |
| A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia (NCT02260635) | Eli Lilly and Company | 2014-11-01 |
| A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (NCT02152631) | Eli Lilly and Company | 2014-10-03 |
| A Study of LY3079514 in Healthy Participants (NCT02242903) | Eli Lilly and Company | 2014-10-01 |
| A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (NCT02227784) | Eli Lilly and Company | 2014-10-01 |
| A Study of LY2835219 in Healthy Participants (NCT02256267) | Eli Lilly and Company | 2014-10-01 |
| A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA) (NCT02265705) | Eli Lilly and Company | 2014-10-01 |
| A Study to Measure the Amount of Evacetrapib That Enters the Blood Stream in Healthy Participants (NCT02271425) | Eli Lilly and Company | 2014-10-01 |
| A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction (NCT02224846) | Eli Lilly and Company | 2014-10-01 |
| A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan (NCT02248480) | Eli Lilly and Company | 2014-10-01 |
| A Study of How the Body Breaks Down and Eliminates LY2623091 (NCT02242981) | Eli Lilly and Company | 2014-09-01 |
| A Study of Evacetrapib in Healthy Japanese Participants (NCT02226653) | Eli Lilly and Company | 2014-09-01 |
| A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma (NCT02178358) | Eli Lilly and Company | 2014-08-08 |
| A Study of LY2623091 in Participants With High Blood Pressure (NCT02194465) | Eli Lilly and Company | 2014-08-01 |
| A Study of LY2409021 in Healthy Participants (NCT02217618) | Eli Lilly and Company | 2014-08-01 |
| A Study of LY3164530 in Participants With Cancer (NCT02221882) | Eli Lilly and Company | 2014-08-01 |
| A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer (NCT02107703) | Eli Lilly and Company | 2014-07-22 |
| A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache (NCT02163993) | Eli Lilly and Company | 2014-07-07 |
| A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics (NCT02197520) | Eli Lilly and Company | 2014-07-01 |
| Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) (NCT01870284) | Eli Lilly and Company | 2014-07-01 |
| A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain (NCT02192190) | Eli Lilly and Company | 2014-07-01 |
| A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (NCT02124148) | Eli Lilly and Company | 2014-06-18 |
| Safety Study of LY3041658 in Healthy Participants (NCT02148627) | Eli Lilly and Company | 2014-06-16 |
| A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread (NCT02102490) | Eli Lilly and Company | 2014-06-10 |
| A Study of LY3050258 in Healthy Participants (NCT02121834) | Eli Lilly and Company | 2014-06-01 |
| A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes (NCT02806960) | Eli Lilly and Company | 2014-06-01 |
| A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements (NCT02152384) | Eli Lilly and Company | 2014-06-01 |
| Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis (NCT02144272) | Eli Lilly and Company | 2014-06-01 |
| A Study of LY2951742 in Healthy Japanese and Caucasian Participants (NCT02104765) | Eli Lilly and Company | 2014-06-01 |
| A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants (NCT02156492) | Eli Lilly and Company | 2014-06-01 |
| Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants (NCT02161731) | Eli Lilly and Company | 2014-06-01 |
| A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis (NCT02144285) | Eli Lilly and Company | 2014-06-01 |
| A Study of Cephalexin Suspension in Healthy Participants (NCT02123459) | Eli Lilly and Company | 2014-05-01 |
| A Study of Evacetrapib in Participants With Abnormal Cholesterol (NCT02168803) | Eli Lilly and Company | 2014-05-01 |
| A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants (NCT02111083) | Eli Lilly and Company | 2014-05-01 |
| A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body (NCT02154646) | Eli Lilly and Company | 2014-05-01 |
| A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants (NCT02123472) | Eli Lilly and Company | 2014-05-01 |
| A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes (NCT02152371) | Eli Lilly and Company | 2014-05-01 |
| Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia (NCT02171130) | Eli Lilly and Company | 2014-05-01 |
| A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes (NCT02132637) | Eli Lilly and Company | 2014-05-01 |
| A Study of LY2835219 in Participants With Cancer (NCT02117648) | Eli Lilly and Company | 2014-04-01 |
| A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus (NCT02111096) | Eli Lilly and Company | 2014-04-01 |
| A Study of Cephalexin Capsules in Healthy Participants (NCT02123446) | Eli Lilly and Company | 2014-04-01 |
| A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue (NCT02109029) | Eli Lilly and Company | 2014-04-01 |
| A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants (NCT02109042) | Eli Lilly and Company | 2014-04-01 |
| A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (NCT02069041) | Eli Lilly and Company | 2014-04-01 |
| A Study of Cephalexin in Healthy Participants (NCT02100826) | Eli Lilly and Company | 2014-04-01 |
| A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) (NCT02079636) | Eli Lilly and Company | 2014-03-28 |
| A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (NCT02057133) | Eli Lilly and Company | 2014-03-10 |
| A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer (NCT02082210) | Eli Lilly and Company | 2014-03-07 |
| A Study of Galunisertib in Participants With Myelodysplastic Syndromes (NCT02008318) | Eli Lilly and Company | 2014-03-01 |
| A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus (NCT02091362) | Eli Lilly and Company | 2014-03-01 |
| Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (NCT02008357) | Eli Lilly and Company | 2014-02-28 |
| A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH) (NCT01824290) | Eli Lilly and Company | 2014-02-05 |
| A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (NCT02072096) | Eli Lilly and Company | 2014-02-01 |
| A Study of LY2835219 in Healthy Participants (NCT02059148) | Eli Lilly and Company | 2014-02-01 |
| A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus (NCT02041091) | Eli Lilly and Company | 2014-01-01 |
| A Study of LY2835219 in Japanese Participants With Advanced Cancer (NCT02014129) | Eli Lilly and Company | 2013-12-18 |
| A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer (NCT01983878) | Eli Lilly and Company | 2013-12-01 |
| A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes (NCT02020616) | Eli Lilly and Company | 2013-12-01 |
| A Study of Insulin Peglispro in Healthy Male Japanese Participants (NCT01995526) | Eli Lilly and Company | 2013-12-01 |
| A Study of LY2969822 in Healthy Participants (NCT02018887) | Eli Lilly and Company | 2013-12-01 |
| A Study of Axiron® in Healthy Participants (NCT02004132) | Eli Lilly and Company | 2013-12-01 |
| A Study of LY2928057 in Hemodialysis Participants (NCT01991483) | Eli Lilly and Company | 2013-12-01 |
| A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes (NCT01995656) | Eli Lilly and Company | 2013-12-01 |
| A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body (NCT02014116) | Eli Lilly and Company | 2013-11-26 |
| A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (NCT02009449) | Eli Lilly and Company | 2013-11-15 |
| Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes (NCT01997411) | Eli Lilly and Company | 2013-11-01 |